The immunopotentiator CVC1302 enhances immune efficacy and protective ability of foot-and-mouth disease virus vaccine in pigs

Jin Chen; Xiaoming Yu; Qisheng Zheng; Liting Hou; Luping Du; Yuanpeng Zhang; Xuwen Qiao; Jibo Hou; Kehe Huang

doi:10.1016/j.vaccine.2018.11.012

The immunopotentiator CVC1302 enhances immune efficacy and protective ability of foot-and-mouth disease virus vaccine in pigs

Vaccine. 2018 Dec 18;36(52):7929-7935. doi: 10.1016/j.vaccine.2018.11.012. Epub 2018 Nov 20.

Authors

Jin Chen¹, Xiaoming Yu², Qisheng Zheng², Liting Hou², Luping Du², Yuanpeng Zhang², Xuwen Qiao², Jibo Hou², Kehe Huang³

Affiliations

¹ College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China; China Institute of Nutritional and Metabolic Disorders in Domestic Animals and Fowls, Nanjing Agricultural University, Nanjing 210095, China; Institute of Veterinary Immunology & Engineering, Jiangsu Academy of Agricultural Sciences, Nanjing, Jiangsu 210014, China; Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou 225009, China.
² Institute of Veterinary Immunology & Engineering, Jiangsu Academy of Agricultural Sciences, Nanjing, Jiangsu 210014, China; Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou 225009, China.
³ College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China; China Institute of Nutritional and Metabolic Disorders in Domestic Animals and Fowls, Nanjing Agricultural University, Nanjing 210095, China. Electronic address: khhuang@njau.edu.cn.

PMID: 30470640
DOI: 10.1016/j.vaccine.2018.11.012

Abstract

The immunological enhancement characteristics of the immunopotentiator CVC1302 were evaluated for foot-and-mouth disease virus (FMDV) inactivated vaccine in pigs. Eight-week-old piglets were vaccinated with the foot-and-mouth disease (FMD) vaccine alone (FMD-vaccine group) or with the addition of CVC1302 (FMD-CVC1302 group), and the serum liquid phase blocking ELISA (LPB-ELISA) antibody titers, IgG1 and IgG2 levels, and the levels of four cytokines secreted by peripheral blood lymphocytes were measured at 28 days post vaccination (dpv). In the FMD-CVC1302 group, the LPB-ELISA antibody titers, IgG1, and IgG2 titers, and IL-2, IL-4, IL-6, and IFN-γ levels at 28 dpv were significantly higher than those in the FMD-vaccine group. The FMD-CVC1302 group had long-lasting antibody titers (>7.8 log₂), lasting for at least 6 months. In addition, piglets were vaccinated with or without addition of CVC1302 to the FMD vaccine at three different doses (1, 1/3, and 1/9 of the standard vaccine dose) and the serum LPB-ELISA antibody and serum neutralizing (SN) antibody titers were detected at 28 dpv. Then all pigs were challenged with virulent FMDV for PD₅₀ value, and the levels of FMDV-specific RNA copies for the two full-dose groups at 3 and 10 days post challenge (dpc) were measured. The LPB-ELISA and SN antibody titers for the three doses in the FMD-CVC1302 groups were significantly higher than those in the FMD-vaccine groups at the same doses (p < 0.05). Post-virus challenge, the FMDV-specific RNA copy number in the FMD-CVC1302 group was lower than that in the FMD-vaccine group at 3 and 10 dpc. The PD₅₀ value was 15.85 for the FMD-CVC1302 group, which was obviously higher than that for the FMD-vaccine group (10.96), and in the 1/9-dose of FMD-vaccine group only 3/5 pigs were protected. These results indicate that CVC1302 can enhance the immune efficacy and protective ability of the FMD vaccine in pigs.

Keywords: Foot-and-mouth disease virus; Immune efficacy; Immunopotentiator CVC1302; Inactivated vaccine.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adjuvants, Immunologic / administration & dosage*
Animals
Antibodies, Neutralizing / blood
Antibodies, Viral / blood
Cytokines / immunology
Foot-and-Mouth Disease / prevention & control*
Foot-and-Mouth Disease Virus
Immunoglobulin G / blood
Swine
Swine Diseases / prevention & control*
Swine Diseases / virology
Vaccines, Inactivated / immunology
Viral Vaccines / immunology*

Substances

Adjuvants, Immunologic
Antibodies, Neutralizing
Antibodies, Viral
Cytokines
Immunoglobulin G
Vaccines, Inactivated
Viral Vaccines